Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma

Benjamin Gallo Marin; Rocío Oliva; Benjamin Kahn; Theo Borgovan; Blake Elizabeth Brooks; Cathy M Massoud

Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma

R I Med J (2013). 2022 Apr 1;105(3):34-36.

Authors

Benjamin Gallo Marin¹, Rocío Oliva¹, Benjamin Kahn¹, Theo Borgovan², Blake Elizabeth Brooks¹, Cathy M Massoud¹

Affiliations

¹ Brown Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
² Division of Hematology and Oncology, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island.

PMID: 35349618
PMCID: PMC9053295

Abstract

Adverse cutaneous reactions associated with the immune checkpoint inhibitor (ICI) pembrolizumab are well documented, yet life-threatening reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are infrequent.1,2 We present a case of pembrolizumab-induced TEN in a patient with metastatic esophageal adenocarcinoma who was successfully treated with cyclosporine and systemic corticosteroids.

Keywords: Stevens-Johnson syndrome; cyclosporine; pembrolizumab; toxic epidermal necrolysis.

Publication types

Case Reports

MeSH terms

Adenocarcinoma* / drug therapy
Antibodies, Monoclonal, Humanized / adverse effects
Humans
Skin
Stevens-Johnson Syndrome* / etiology
Stevens-Johnson Syndrome* / therapy

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab

Grants and funding

R25 AI140490/AI/NIAID NIH HHS/United States